Huntington's Disease Treatment Market - Top Companies and Manufacturers

Companies Dominating the Huntingtonâ€™s Disease Treatment Landscape

Huntington’s disease treatment market is projected to have a steady growth during the forecast period. Key market players are investing in research and development to reduce side effects of HD treatment drugs, and provide better palliative care for patients.

Some of the key market players are:

Teva Pharmaceuticals Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
UniQure
Lupin
Dr. Reddy’s Laboratories Ltd.
Neurocrine Biosciences Ltd.
Sun Pharmaceutical Industries Ltd.
Pfizer, Inc.
Lundbeck A/S
Bausch Health Companies Inc.
Hikma Pharmaceuticals PLC
Ionis Pharmaceuticals
Sage Therapeutics
WaVe Life Sciences
Azevan Pharmaceuticals

Browse Key Market Insights with Data Illustration:

Huntington's Disease Treatment Market Size & Share, Forecast Report 2037

In the News

In July 2024, UniQure’s stocks saw a surge of 60% as the company updated on the clinical trials for its gene therapy AMT-130 for Huntington’s disease. The company updates that higher dose of AMT-130 is decelerating the progression of Huntington’s.
In May 2024, Teva announced Austedo extended-release tablets approved by the U.S. FDA as a one pill, daily treatment for clinically therapeutic doses.
In May 2024, Evotec and CHDI Foundation extended their 20-year collaboration that is dedicated to developing therapeutics to improve lives of people afflicted with Huntington’s disease.
In March 2023, Aitia and UCB announced a strategic collaboration for drug discovery in Huntington’s disease. The collaboration is aimed at early drug discovery and validation of novel drug targets.

Frequently Asked Questions (FAQ)

The huntington's disease treatment market was estimated at USD 555.4 million in 2024 and registered a CAGR of 21.5% during the forecast period, i.e., 2025-2037.

The huntington's disease treatment market registered a valuation of USD 555.4 million 2024 and is poised to attain USD 6.9 billion by 2037 at a profitable CAGR of 21.5% during the forecast period, i.e., 2025-2037.

The major players in the market are Teva Pharmaceuticals Industries Ltd., UniQure, Lupin, Wave Life Sciences, Azevan Pharmaceuticals, Dr. Reddyâ€™s Laboratories Ltd., Neurocrine Biosciences Ltd., and others.

The tetrabenazine (Xenazine/Nitoman) segment registered the highest revenue share in the global market with a 53.6% market share in 2024 and is poised to increase its revenue share by the end of 2037.

North America is estimated to provide the most opportunities by 2037 and is poised to register a 34.8% revenue share in the global market owing to rising demands for huntington's disease treatment.

Huntington's Disease Treatment Market - Top Companies and Manufacturers

Companies Dominating the Huntingtonâ€™s Disease Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the huntington's disease treatment market?

What is the outlook for the huntington's disease treatment market?

Who are the major players dominating the huntington's disease treatment market?

Which product segment will capture the significant market share for the huntington's disease treatments sector by 2037?

Which region will provide more business opportunities for the growth of the huntington's disease treatment market in the future?